Enveric Biosciences Inc Total Assets
Enveric Biosciences Inc total assets. Based on the latest financial reports, Enveric Biosciences Inc (ENVB) holds total assets worth $4.36 Million USD as of September 2025. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. Also see ENVB company net worth for the company's overall valuation and market capitalisation.
Total Assets of Enveric Biosciences Inc (1994–2024)
Total assets of Enveric Biosciences Inc from 1994 to 2024. This chart illustrates how Enveric Biosciences Inc's total assets have evolved over time, based on quarterly financial data. See ENVB share price today for real-time trading data and today's change.
Enveric Biosciences Inc - Asset Composition Analysis
Enveric Biosciences Inc Total Assets Breakdown (December 2024)
Enveric Biosciences Inc total assets breakdown as of December 2024. Enveric Biosciences Inc's total assets of $4.36 Million consist of 88.7% current assets and 11.3% non-current assets.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 72.7% |
| Accounts Receivable | $0.00 | 0.0% |
| Inventory | $0.00 | 0.0% |
| Property, Plant & Equipment | $0.00 | 0.0% |
| Intangible Assets | $42.18K | 1.4% |
| Goodwill | $0.00 | 0.0% |
Asset Composition Trend (1994–2024)
This chart illustrates how Enveric Biosciences Inc's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. Explore Enveric Biosciences Inc short-term liquidity ratio to assess how much short-term liquidity the company maintains relative to its equity base.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Enveric Biosciences Inc's current assets represent 88.7% of total assets in 2024, an increase from 82.6% in 1994.
- Cash Position: Cash and equivalents constituted 72.7% of total assets in 2024, up from 65.2% in 1994.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 1.0% of total assets, an increase from 0.0% in 1994.
- Asset Diversification: The largest asset category is intangible assets at 1.4% of total assets.
Enveric Biosciences Inc Competitors by Total Assets
Key competitors of Enveric Biosciences Inc based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Hyloris Developmentsen Sa
BR:HYL
|
Belgium | €37.05 Million |
|
Biomarin Pharmaceutical Inc
NASDAQ:BMRN
|
USA | $11.72 Billion |
|
Oruka Therapeutics, Inc.
NASDAQ:ORKA
|
USA | $1.14 Billion |
|
Gempharmatech Co. Ltd. A
SHG:688046
|
China | CN¥2.80 Billion |
|
Vor Biopharma Inc
NASDAQ:VOR
|
USA | $481.05 Million |
|
Inventiva S.A
PA:IVA
|
France | €249.51 Million |
|
Sunmax Biotechnology Co Ltd
TWO:4728
|
Taiwan | NT$1.90 Billion |
|
Apnimed, Inc. Common Stock
NASDAQ:APMD
|
USA | $342.63 Million |
Enveric Biosciences Inc - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 4.60 | 5.17 | 3.35 |
| Quick Ratio | 4.60 | 5.19 | 3.35 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | $3.26 Million | $3.50 Million | $1.60 Million |
Enveric Biosciences Inc - Advanced Valuation Insights
This section examines the relationship between Enveric Biosciences Inc's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 0.84 |
| Latest Market Cap to Assets Ratio | 0.25 |
| Asset Growth Rate (YoY) | -28.3% |
| Total Assets | $3.08 Million |
| Market Capitalization | $777.45K USD |
Valuation Analysis
Below Book Valuation: The market values Enveric Biosciences Inc's assets below their book value (0.25x), which may indicate investor concerns about asset quality or future growth.
Significant Asset Reduction: Enveric Biosciences Inc's assets decreased by 28.3% over the past year, potentially indicating divestiture, restructuring, or challenging business conditions.
Annual Total Assets for Enveric Biosciences Inc (1994–2024)
The table below shows the annual total assets of Enveric Biosciences Inc from 1994 to 2024.
| Year | Total Assets | Change |
|---|---|---|
| 2024-12-31 | $3.08 Million | -28.31% |
| 2023-12-31 | $4.30 Million | -78.01% |
| 2022-12-31 | $19.55 Million | -26.82% |
| 2021-12-31 | $26.72 Million | +552.18% |
| 2020-12-31 | $4.10 Million | -83.62% |
| 2019-12-31 | $25.01 Million | -15.63% |
| 2018-12-31 | $29.64 Million | -43.22% |
| 2017-12-31 | $52.20 Million | +32.12% |
| 2016-12-31 | $39.51 Million | +185.57% |
| 2015-12-31 | $13.83 Million | +271973.43% |
| 2014-12-31 | $5.08K | +13.81% |
| 2013-12-31 | $4.47K | -20.21% |
| 2012-12-31 | $5.60K | -75.06% |
| 2011-12-31 | $22.45K | +1893.78% |
| 2010-12-31 | $1.13K | -37.17% |
| 2009-12-31 | $1.79K | -97.43% |
| 2008-12-31 | $69.67K | -95.66% |
| 2007-12-31 | $1.61 Million | +246.22% |
| 2006-12-31 | $463.58K | -48.31% |
| 2005-12-31 | $896.92K | -38.74% |
| 2004-12-31 | $1.46 Million | +21.48% |
| 2003-12-31 | $1.21 Million | -30.97% |
| 2002-12-31 | $1.75 Million | -0.41% |
| 2001-12-31 | $1.75 Million | -28.65% |
| 2000-12-31 | $2.46 Million | +16.01% |
| 1999-12-31 | $2.12 Million | +137.06% |
| 1998-12-31 | $893.45K | -71.77% |
| 1997-12-31 | $3.17 Million | -23.57% |
| 1996-12-31 | $4.14 Million | -5.88% |
| 1995-12-31 | $4.40 Million | +91.30% |
| 1994-12-31 | $2.30 Million | -- |
About Enveric Biosciences Inc
Enveric Biosciences, Inc., a biotechnology company, engages in the development of small-molecule therapeutics for the treatment of anxiety, depression, and addiction disorders. The company offers product candidates are EB-002, an active metabolite of psilocybin, which is in preclinical development stage for the treatment of anxiety disorders; and EB-003 that is in preclinical development stage fo… Read more